Oxbridge Re (NASDAQ:OXBR – Get Rating) is scheduled to be posting its quarterly earnings results after the market closes on Monday, November 14th. Individual interested in participating in the company’s earnings conference call can do so using this link.
Oxbridge Re (NASDAQ:OXBR – Get Rating) last released its earnings results on Monday, August 15th. The insurance provider reported $0.01 EPS for the quarter. The firm had revenue of $0.50 million during the quarter.
Oxbridge Re Stock Performance
NASDAQ OXBR opened at $1.88 on Friday. The stock has a market capitalization of $10.87 million, a price-to-earnings ratio of 1.39 and a beta of 1.05. The stock’s 50 day moving average price is $2.21 and its two-hundred day moving average price is $3.27. Oxbridge Re has a 52 week low of $1.84 and a 52 week high of $7.13.
Analyst Ratings Changes
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Oxbridge Re stock. Dimensional Fund Advisors LP increased its holdings in shares of Oxbridge Re Holdings Limited (NASDAQ:OXBR – Get Rating) by 19.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 54,753 shares of the insurance provider’s stock after acquiring an additional 9,026 shares during the quarter. Dimensional Fund Advisors LP owned about 0.95% of Oxbridge Re worth $299,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 21.68% of the company’s stock.
About Oxbridge Re
Oxbridge Re Holdings Limited, together with its subsidiaries, provides specialty property and casualty reinsurance solutions. It underwrites reinsurance contracts primarily for property and casualty insurance companies in the Gulf Coast region of the United States. The company distributes its products and solutions through reinsurance brokers.
- Get a free copy of the StockNews.com research report on Oxbridge Re (OXBR)
- MarketBeat: Week in Review 11/7 – 11/11
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn’t Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don’t Want to Get Stuck On
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
Receive News & Ratings for Oxbridge Re Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxbridge Re and related companies with MarketBeat.com's FREE daily email newsletter.